Class / Patent application number | Description | Number of patent applications / Date published |
424167100 | Clostridium (e.g., Clostridium tetani, etc.) | 18 |
20090269358 | Proteins with Improved Solubility and Methods for Producing and Using Same - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 10-29-2009 |
20090274708 | Recombinant Toxin Fragments - Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H | 11-05-2009 |
20090285833 | CLOSTRIDIUM BOTULINUM C3 EXOTRANSFERASE COMPOSITIONS AND METHODS FOR TREATING TUMOUR SPREADING - Pharmaceutical compositions, each consisting of a cell-permeable fusion protein conjugate of a polypeptidic cell-membrane transport moiety and a | 11-19-2009 |
20100166773 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-01-2010 |
20100260778 | SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS - Small-molecule inhibitors of Botulinum toxin, including BoNTA, BoNTD and BoNTE are provided, as well as methods of using the inhibitors. | 10-14-2010 |
20110014211 | COMPOSITION FOR NEUTRALIZING BOTULINUS TOXIN TYPE-A, AND HUMAN ANTI-BOTULINUS TOXIN TYPE-A ANTIBODY - Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity. | 01-20-2011 |
20110200615 | Antibodies that Neutralize Botulinum Neurotoxins - This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 08-18-2011 |
20120003241 | VACCINE AGAINST BOTULISM - The invention relates to novel DNA and protein vaccines against | 01-05-2012 |
20120034239 | PROTEINS WITH IMPROVED SOLUBILITY AND METHODS FOR PRODUCING AND USING SAME - A method is provided for improving the solubility of proteins, for example, bacterial toxins. In one embodiment, solubility is improved by introducing point mutations that replace cysteine residues capable of forming intermolecular disulfide bonds with other amino acid residues that do not form such bonds. By abrogating the ability of the cysteine residues to form inter-molecular disulfide bonds, aggregation of the protein is reduced, thereby improving the solubility of the protein. In another embodiment, solubility of the protein is improved by producing truncated forms of the protein that express the LHN domain and a fragment of the Hc domain. Proteins made according to the method of the invention are useful, for example, as immunodiagnostic agents and vaccine components. | 02-09-2012 |
20120121607 | ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 05-17-2012 |
20120269822 | Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies - Antibodies that bind to | 10-25-2012 |
20120282274 | TARGETING OF THE C-TERMINAL SEGMENT OF C.DIFFICILE TOXIN B FOR IMPROVED CLINICAL DIAGNOSIS, PREVENTION, AND TREATMENT - The disclosure provides specific and sensitive anti-toxin B antibodies and fragments thereof suitable for diagnosing | 11-08-2012 |
20130202618 | ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE - Provided herein are reagents, compositions, and therapies with which to treat | 08-08-2013 |
20130230537 | CLOSTRIDIUM DIFFICILE-SPECIFIC ANTIBODIES AND USES THEREOF - The present invention is directed to | 09-05-2013 |
20130266583 | CLOSTRIDIUM DIFFICILE ANTIGENS - The present invention relates to recombinant | 10-10-2013 |
20140099328 | ANTIBODY PRODUCT COMPRISING N SPECIFIC ANTIBODIES - Antibody product comprising n-specific antibodies
| 04-10-2014 |
20140105910 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and typically neutralize | 04-17-2014 |
20150010580 | ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS - The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of | 01-08-2015 |